Navigation Links
Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
Date:3/31/2008

patients was just over 2 years by which time 20% of the placebo subjects and 48% of those taking medication had achieved the target blood pressure of 150/80 mmHg. In those patients who were followed up for longer, a larger number of patients receiving active treatment achieved the target blood pressure.

HYVET was co-ordinated by scientists from Imperial College London, working with colleagues around the world. The main trial was funded by both the British Heart Foundation and by Servier.

Notes to editors

1. About high blood pressure and stroke

- Stroke is the third most common cause of death in England and Wales. In 2004, 11% of deaths amongst those aged 75-84, and 14% of deaths amongst those aged over 85 were due to stroke, according to the Office of National Statistics.

- In the UK about 150,000 people suffer a stroke each year, the equivalent of 1 every 4 minutes.

- About one third of stroke patients die within 6 months of the event, the majority occurring in the first month.

- Disability after stroke is the most important single cause of severe disability of people living in their own homes.

- There are 2 types of stroke:

a. Haemorrhagic - caused by blood leaking into brain tissue from a blood vessel within the brain.

b. Ischaemic - caused by a clot occluding a blood vessel, resulting in loss of blood supply to a part of the brain and subsequent damage to brain tissue.

High blood pressure increases the chance of both a blood vessel leaking or rupturing, and of a clot forming within a blood vessel. High blood pressure increases the likelihood of damage to the lining of the blood vessel, which in turn leads to an increased chance of spontaneous clot formation within the blood vessel.

- The over 80s are the fastest growing group in the population worldwide - in the UK currently they account for 4% of the total population and this is expected to rise to over 11% by 2050.

- The
'/>"/>

SOURCE Imperial College London
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
2. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
3. Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference
4. InterMune to Present at the SIGnificant Options in Healthcare Conference
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
7. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
8. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
9. AMDL Receives a Significant Updated Appraisal of Its JJB China Production Facilities
10. Significant Progress Made in Nations Preparedness to Respond to Public Health Emergencies; But Gaps in Critical Areas Threaten Overall Readiness
11. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3